NPS Medicinewise says the PBAC
approval of Pradaxa, Xarelto and
Eliquis (PD yesterday) means health
professionals should weigh the risks
and benefits of switching to these
oral anticoagulants.
NPS ceo Lynn Weekes said that
while the subsidy of the newer
products offers greater choice for
GPs and their patients, evidence
suggests people with non-valvular
AF whose anticoagulation is well
controlled using warfarin may not
benefit clinically from switching.The above article was sent to subscribers in Pharmacy Daily's issue from 30 Apr 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Apr 13
RESPONDING to the findings from the Royal Commission into Aged Care Quality and Safety, a recent government initiative aims to improve medication management in residential aged care facilities by introducing on-site pharmacists.
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.